Michael Stanford Acquires 40,000 Shares of Healius Limited (ASX:HLS) Stock

Healius Limited (ASX:HLS) insider Michael Stanford purchased 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were bought at an average cost of A$1.33 ($0.86) per share, with a total value of A$53,200.00 ($34,545.45).

Healius Price Performance

The company has a current ratio of 0.50, a quick ratio of 0.47 and a debt-to-equity ratio of 153.54.

About Healius

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands.